TFBC Combined With UCBT in the Treatment of High-risk Malignant Hematological Diseases
Hematopoietic Stem Cell Transplantation, Malignant Hematological Diseases
About this trial
This is an interventional treatment trial for Hematopoietic Stem Cell Transplantation focused on measuring Umbilical Cord Blood Transplantation; Conditioning regimen
Eligibility Criteria
Inclusion Criteria: Gender is not limited, patients between 14 to 70 years old (including critical value); High-risk malignant hematological diseases (acute lymphoblastic leukemia, acute/chronic myeloid leukemia, multiple myeloma, etc.) diagnosed by bone marrow aspiration or biopsy according to the WHO diagnostic criteria; The indexes of cardiac function, liver and kidney function were within the following limits:(1) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 3× Upper limit of normal (ULN); (2)Total bilirubin ≤ 3×ULN; (3) Serum creatinine ≤ 2×ULN or creatinine clearance ≥ 40mL/min; (4) Left ventricular ejection fraction (LVEF) as measured by echocardiography or multi-gated acquisition (MUGA) scan is within the normal range (> 50%); Umbilical cord blood with HLA match ≥ 4/6; Expected survival ≥3 months; Karnofsky (KPS) score ≥60%, Eastern Tumor Cooperative group (ECOG) status ≤ 2; Patient fully understood the nature of the study, and voluntarily participates and signs informed consent. Exclusion Criteria: Patients had serious adverse reactions to investigational drugs such as allergies; Patients with a history of immunodeficiency, or other acquired or congenital diseases, immunodeficiency diseases, and a history of organ transplantation; Patients with hypertension, ventricular arrhythmia requiring clinical intervention, acute coronary syndrome, congestive heart failure, stroke, or other grade III or higher cardiovascular events within 6 months; Two or more surgeries were performed within 4 weeks prior to enrollment; Patients with active viral infections, including HIV, HBV, HCV, TP; Pregnant or lactating patients; The patient is currently participating in another clinical studies; Patients deemed unsuitable for inclusion by other investigators.
Sites / Locations
- The First Affiliated Hospital of Soochow universityRecruiting
Arms of the Study
Arm 1
Experimental
40 patients with malignant hematological diseases who underwent UCBT